Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma.
about
Oligodendroglioma: pathology, molecular mechanisms and markersComprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas.Molecular Markers in Low-Grade Glioma-Toward Tumor ReclassificationEmerging targeted therapies for glioma.Multidimensional scaling of diffuse gliomas: application to the 2016 World Health Organization classification system with prognostically relevant molecular subtype discovery.IDH mutant and 1p/19q co-deleted oligodendrogliomas: tumor grade stratification using diffusion-, susceptibility-, and perfusion-weighted MRIIDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas.CDKN2A loss is associated with shortened overall survival in lower-grade (World Health Organization Grades II-III) astrocytomas.Automated Analysis of 1p/19q Status by FISH in Oligodendroglial Tumors: Rationale and Proposal of an Algorithm.Molecular-genetic and clinical characteristics of gliomas with astrocytic appearance and total 1p19q loss in a single institutional consecutive cohort.Contribution of 1p, 19q, 9p and 10q Automated Analysis by FISH to the Diagnosis and Prognosis of Oligodendroglial Tumors According to WHO 2016 Guidelines.IDH mutation status is associated with a distinct hypoxia/angiogenesis transcriptome signature which is non-invasively predictable with rCBV imaging in human glioma.Farewell to GBM-O: Genomic and transcriptomic profiling of glioblastoma with oligodendroglioma component reveals distinct molecular subgroups.5-hydroxymethylcytosine loss is associated with poor prognosis for patients with WHO grade II diffuse astrocytomas.Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial.A multi-resolution textural approach to diagnostic neuropathology reporting.Detection of ATRX and IDH1-R132H immunohistochemistry in the progression of 211 paired gliomasPrognostic value of the extent of resection in supratentorial WHO grade II astrocytomas stratified for IDH1 mutation status: a single-center volumetric analysisNeurosurgery concepts: Key perspectives on intrathecal fluorescein for detecting intraoperative cerebrospinal fluid leak during endoscopic endonasal surgery, spinal intraarterial chemotherapy, oligoastrocytoma classification by in situ molecular genNot all 1p/19q non-codeleted oligodendroglial tumors are astrocytic.Specific monoclonal antibodies against IDH1/2 mutations as diagnostic tools for gliomas.Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide.Diagnostic, prognostic and predictive relevance of molecular markers in gliomas.Diffusely infiltrating astrocytomas: pathology, molecular mechanisms and markers.Beyond the World Health Organization grading of infiltrating gliomas: advances in the molecular genetics of glioma classification.Impending Impact of Molecular Pathology on Classifying Adult Diffuse Gliomas.Seizures in oligodendroglial tumors.Identification of a novel inactivating mutation in Isocitrate Dehydrogenase 1 (IDH1-R314C) in a high grade astrocytoma.Advances in the molecular genetics of gliomas - implications for classification and therapy.Further understanding of the pathology of glioma: implications for the clinic.Recent Advances on the Molecular Pathology of Glial Neoplasms in Children and Adults.The Role of Molecular Diagnostics in the Management of Patients with Gliomas.Prognostic impact of the 2016 WHO classification of diffuse gliomas in the French POLA cohort.Feline glioma: a retrospective study and review of the literature.Diffuse low-grade glioma: a review on the new molecular classification, natural history and current management strategies.Completeness of required site-specific factors for brain and CNS tumors in the Surveillance, Epidemiology and End Results (SEER) 18 database (2004-2012, varying).Chromosome 17p Homodisomy Is Associated With Better Outcome in 1p19q Non-Codeleted and IDH-Mutated Gliomas.Defining neoplastic diseases differently: An emerging paradigm from The Cancer Genome Atlas lower-grade gliomas project.Molecular Diagnostics of Gliomas Using Next Generation Sequencing of a Glioma-Tailored Gene Panel.Genomic profiling of lower-grade gliomas uncovers cohesive disease groups: implications for diagnosis and treatment.
P2860
Q27002448-E93D8BB0-DEF6-4032-B71B-6911B4B7F741Q27853175-F19C35FF-0CAE-4D48-9A55-399EBD6AC579Q28383205-2950CF2A-F8D9-4676-9808-4B33FF7580D0Q30241853-B24FCF9D-6A81-4081-AF4B-B441E7641002Q33711322-63341DF0-883F-4D11-8BA3-2A9297CD8BBBQ33733375-D66E3516-4457-4E0E-849F-31BA1CBDB554Q35204658-E99FD56A-5C63-4FB1-985C-2C9097CE6E2FQ35418206-411CCEB1-F895-4BBC-A04F-9F017834AEADQ35681251-F73A605E-FC8A-444E-B47E-B9AF3A1B7CE9Q36140650-8913F5AD-189E-4CA0-B591-4F21B8B7C196Q36234884-9771C793-DA5D-4725-903F-36D02D1C7289Q36249897-49FE8213-36E4-4D1E-B1F0-D39DFB1736F0Q36457608-07FE1D40-F9CD-430C-B8C3-3FE8E35ACA81Q36569563-523BE997-AC73-4A30-8207-B8E48CE3DE6AQ36618241-D6E6EBB5-8D17-4F4E-88A0-BEC2836D346FQ36663072-B8E8E9C0-9C88-43BC-AB5B-6A7143C44233Q37086042-1475F3AA-05DB-41D2-AE32-5AD013189B57Q37191509-387246DC-BC95-475E-9025-3FA9077EDF9EQ37390588-6283B587-00F3-493C-93CB-5FD922EB93EBQ37662100-071C0107-8567-4146-956F-6603B82B9269Q38260977-61E28076-EF1C-4AFB-AFCD-A72CC33143DFQ38390616-8434D3A2-760D-4790-8D52-F222FD53498DQ38461565-CD7B75E4-819A-4A1A-BB13-615CD5D7E5FFQ38480437-F855990F-AB25-4693-A4B3-C43C63E9A17EQ38504172-3A4BC6F5-9910-4A3F-820F-D3A8940412F2Q38526029-AD34CC99-AE81-46B1-BC04-BD3AD73CE120Q38610571-9DB770C6-D1BF-49C3-8E51-357312B4C7AAQ38755638-B15E56E0-36AF-4568-9E60-002523CF77FEQ38777058-3426AB53-8C72-471F-9C6B-87B9F211327FQ38844945-3B4EFF53-FFD1-4708-8406-A9B19F6C925FQ38905187-342D5410-D57D-47DD-ABA5-74E00C7A72C5Q38921975-3F0CD6CB-C045-4C16-B221-5C90C0E73B25Q38940482-008FF643-94A8-4A42-B40F-10BAAB13375CQ39117503-990C9EF8-37E0-4AE9-8634-5D1E2C17A794Q39159242-16F3C388-B7C9-4CEF-B36B-1B5EE6EFA0EEQ39600412-171B41AA-F9A8-4BC5-AC3F-4C13B06CBC05Q39612508-925064E3-7B33-4233-918F-0BDEC9F96440Q39679490-C651B111-F8D8-476A-84A7-BCB7F39C7971Q39965737-C28BE03E-1BA5-4261-9430-FA40A4EA1F26Q40116779-2D974D8E-A015-4B00-90EB-6F49368561B9
P2860
Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Farewell to oligoastrocytoma: ...... godendroglioma or astrocytoma.
@en
Farewell to oligoastrocytoma: ...... godendroglioma or astrocytoma.
@nl
type
label
Farewell to oligoastrocytoma: ...... godendroglioma or astrocytoma.
@en
Farewell to oligoastrocytoma: ...... godendroglioma or astrocytoma.
@nl
prefLabel
Farewell to oligoastrocytoma: ...... godendroglioma or astrocytoma.
@en
Farewell to oligoastrocytoma: ...... godendroglioma or astrocytoma.
@nl
P2093
P2860
P50
P1476
Farewell to oligoastrocytoma: ...... godendroglioma or astrocytoma.
@en
P2093
Christian Hartmann
Christian Koelsche
David Reuss
David T W Jones
Stephanie Heim
Werner Paulus
Wolf Mueller
P2860
P2888
P304
P356
10.1007/S00401-014-1326-7
P50
P577
2014-08-21T00:00:00Z